DVA Chart

1 Month

	Date	Diff
	2025-04-23	+2.93 %
DaVita (DVA) stock rose by 2.93% amidst a challenging first quarter for the healthcare sector marked by ransomware attacks, including one impacting DaVita, as the company effectively managed operations during the incident, maintaining continuity of care for patients.
	2025-04-15	-3.05 %
DaVita Inc. (DVA) stock fell by 3.05% likely due to LPL Financial LLC reducing its stake in the company by 26.1% and a mix of institutional investors adjusting their holdings, which can create a negative perception in the market. DaVita's stock (DVA) fell by 3% due to a ransomware attack affecting its operations, which the company is still investigating for its potential impact. DaVita (DVA) stock declined by 3.05% following a ransomware attack over the weekend that encrypted some of its systems, leading to disruptions in their operations and prompting the company to release a public update about service difficulties. DaVita (DVA) stock fell by 2.8% due to the announcement of a ransomware attack impacting some of its operations, which the company is still investigating to determine its full consequences.
	2025-04-14	-2.98 %
DaVita (DVA) stock fell by 2.98% following the company's disclosure of a ransomware attack in a recent SEC filing, which likely raised concerns among investors regarding its operational security and potential impacts on business.
	2025-04-07	-1.93 %
DaVita Inc. (NYSE:DVA) stock fell by 1.93% due to Orion Portfolio Solutions LLC decreasing its stake in the company by 14.4%, along with other hedge funds making changes to their holdings, which may have influenced investor sentiment regarding the stock.
	2025-04-02	+1.57 %
DaVita (DVA) stock rose 1.57% despite being downgraded from a "buy" to a "hold" rating, likely due to positive earnings results that exceeded analysts' expectations and ongoing interest from institutional investors.
	2025-04-01	-0.69 %
DaVita (DVA) stock decreased by 0.69%, primarily due to market concerns regarding the potential negative impact of glucagon-like-peptide-1 (GLP-1) weight-loss drugs on the demand for dialysis services, as highlighted by recent clinical data.
	2025-03-27	+0.75 %
DaVita Inc. (DVA) stock rose by 0.75% after multiple institutional investors, including Raymond James Financial Inc., increased their stakes in the company, signaling strong interest and confidence in its future performance.
	2025-03-18	+0.09 %
DaVita Inc. (NYSE:DVA) stock rose 0.09% partly due to positive analyst ratings and increased target prices from firms such as Barclays and Sanford C. Bernstein, alongside significant investments from institutional investors.
	2025-03-14	+1.65 %
DaVita Inc. (DVA) stock rose by 1.65% following a significant increase in institutional investments, particularly by Assetmark Inc., which raised its position in the company by 756.4%, signaling bullish investor sentiment and confidence in DaVita's performance and future prospects.
	2025-03-12	-2.73 %
DaVita Inc. (NYSE:DVA) stock fell by 2.73% following a period of mixed sentiment among investors and analysts, with many large institutional investors recently changing their positions, but a consensus rating of "Hold" suggests uncertainty about the company's near-term prospects. The decline may also be influenced by market volatility and the recent adjustments in institutional holdings. DaVita Inc. (DVA) stock experienced a decline of -2.73% due to Charles Schwab Investment Management Inc. reducing its stake in the company by 2.5%, alongside other institutional investors adjusting their positions, while the overall market sentiment reflected a consensus rating of "Hold" among analysts. DaVita Inc. (NYSE:DVA) saw its stock fall by 2.73% largely due to Arizona State Retirement System reducing its stake by 11.1% and various other hedge funds adjusting their holdings amidst mixed analyst ratings and recent target price updates.
	2025-03-06	+0.26 %
DaVita (DVA) stock rose 0.26% recently, likely due to its strong market position in kidney care services, its stable business model backed by government reimbursement rates, and the company's significant shareholder buybacks, including those led by Warren Buffett's Berkshire Hathaway, despite concerns about its valuation and debt levels.
	2025-02-28	+0.78 %
DaVita Inc. (DVA) stock saw a modest increase of 0.78% after reporting better-than-expected quarterly earnings, which may have boosted investor confidence despite some institutional selling and mixed analyst ratings.
	2025-02-27	+0.54 %
DaVita Inc. (DVA) stock rose 0.54% likely due to favorable earnings results that exceeded analysts' expectations and positive adjustments in price targets from equity research analysts, despite some institutional investors reducing their stakes in the company.
	2025-02-25	+0.66 %
DaVita Inc. (NYSE:DVA) stock rose by 0.66% following significant increases in institutional investments, including a 59.8% stake increase by Venturi Wealth Management LLC, and positive analyst upgrades, such as Barclays raising its price target, indicating growing confidence in the company's future performance.
	2025-02-19	-0.06 %
DaVita Inc. (DVA) stock experienced a slight decline of 0.06%, attributed to changes in institutional holdings, including a reduction by Chevy Chase Trust Holdings LLC and varying stakes taken by other institutional investors, as well as investors maintaining a cautious stance reflected in the mixed ratings from analysts.
	2025-02-14	-11.09 %
DaVita (DVA) stock fell 13.5% after the company projected annual profit below estimates and following a sell-off of some shares by Warren Buffett's Berkshire Hathaway. DaVita's stock (DVA) fell by over 12% due to a weak profit outlook for 2025 amid rising care costs and increased expenses from center closures, compounded by the news that major investor Berkshire Hathaway sold a significant number of shares. DaVita (DVA) stock fell 13.5% due to Berkshire Hathaway reducing its investment in the kidney dialysis provider. DaVita's stock (DVA) dropped 11.09% following a weak outlook related to increasing care costs and the news that Berkshire Hathaway sold some of its shares as part of a pre-planned agreement.
	2025-02-13	+2.94 %
DaVita (DVA) stock rose by 2.94% due to positive market sentiment and a favorable performance outlook in the healthcare sector, potentially driven by solid earnings reports from comparable companies and general market trends favoring healthcare investments. DaVita Inc. (NYSE:DVA) stock rose 2.94% following increased interest from institutional investors, including a partial sale by Sumitomo Mitsui Trust Group Inc. and raises in holdings by various other firms, as well as an upward adjustment of its target price by Barclays.
	2025-02-10	-0.03 %
DaVita (NYSE:DVA) stock has decreased by 0.03% as it approaches its earnings report, with analysts anticipating earnings of $2.14 per share and revenue of $3.27 billion for the quarter, possibly reflecting cautious investor sentiment ahead of the announcement.
	2025-02-04	+0.16 %
DaVita Inc. (DVA) stock was up 0.16%, likely due to various institutional investors adjusting their positions, including increased investments from several hedge funds and positive price target revisions from analysts.
	2025-01-31	-0.17 %
DaVita Inc. (DVA) stock declined by 0.17% due to the company's recent earnings report, which revealed that it missed consensus earnings expectations by $0.17, despite slightly exceeding revenue estimates.
	2025-01-17	+0.84 %
DaVita Inc. (DVA) stock rose 0.84% following increased investment interest from institutional investors, including a 4% stake increase by the Czech National Bank, contributing to overall positive market sentiment around the company's growth potential and performance.
	2025-01-02	+0.18 %
DaVita Inc. (DVA) stock rose 0.18% following a notable increase in short interest and positive adjustments to price targets by analysts, indicating investor interest and confidence amid institutional ownership of over 90%.
	2024-12-31	-0.16 %
DaVita Inc. (NYSE:DVA) stock went down by 0.16% to $149.79, primarily due to a mixed performance in earnings results where it missed the consensus estimate, which could have contributed to decreased investor confidence despite positive revenue growth.
	2024-12-24	+1.33 %
DaVita Inc. (NYSE:DVA) stock rose by 1.33% due to positive analyst ratings, including a price target increase from Barclays and Truist Financial, despite its recent quarterly earnings miss, indicating investor confidence in the company's long-term growth potential.
	2024-12-02	-1.46 %
DaVita Inc. (NYSE:DVA) stock experienced a decline of 1.46% following a earnings report that showed the company missed earnings per share estimates, along with a significant insider sell-off by the CEO, raising concerns among investors.
	2024-11-29	+0.33 %
DaVita Inc. (DVA) stock saw a 0.33% increase following notable purchases by several institutional investors and positive adjustments to target prices by analysts, despite the company recently reporting earnings that slightly missed expectations. The stock's rise can largely be attributed to increased institutional investment interest and favorable analyst reports suggesting potential growth, despite mixed earnings results.
	2024-11-20	+2.82 %
DaVita Inc. (DVA) stock rose 2.82% due to a combination of institutional interest, with hedge funds increasing their positions in the company, and a generally positive market response despite recent earnings reports missing expectations. DaVita Inc. (DVA) stock increased by 2.82% following positive adjustments in target prices from several analysts, indicating a favorable outlook despite a missed earnings estimate, and ongoing interest from institutional investors.
	2024-11-04	+2.37 %
DaVita Inc. (NYSE:DVA) stock rose 2.37% due to increased institutional investment, with several hedge funds boosting their stakes and positive adjustments from analysts on the company's price targets, despite a slight miss in earnings per share in the latest quarterly report.
	2024-11-01	+1.27 %
DaVita Inc. (NYSE:DVA) experienced a 1.27% stock increase, attributed to institutional investors raising their positions and a steady revenue growth reported in recent earnings despite slightly missing EPS estimates. DaVita Inc. (DVA) stock prices rose by 1.27% after analysts upgraded their ratings and price targets despite the company reporting weaker-than-expected quarterly earnings, leading to increased investor confidence. The stock's increase can be attributed to analysts' positive adjustments to their ratings and price targets, which suggest future value, despite the recent earnings miss.
	2024-10-31	-1 %
DaVita Inc. (DVA) stock decreased by 1.0% after reporting a quarterly earnings miss, with earnings per share of $2.59 falling short of the expected $2.76. DaVita Inc. (DVA) stock declined by 1.0% after International Assets Investment Management LLC reported purchasing a new position in the company, indicating changes in investor sentiment or market conditions that may have affected its stock performance.
	2024-10-29	+0.8 %
DaVita Inc. (DVA) stock rose 0.8% following an increase in institutional holdings and positive analyst upgrades, with multiple hedge funds increasing their positions in the company, indicating growing investor confidence. The DaVita (DVA) stock rose 0.8% last night, likely due to overall positive market trends and investor confidence in the healthcare sector, following strong performance in the broader equity markets and solid earnings reports from other companies. DaVita (DVA) stock was up 0.8% last night, likely due to positive market conditions influenced by gains in banking stocks and a broader firm trend in global markets.
	2024-10-28	+0.04 %
DaVita Inc. (DVA) stock saw a slight increase of 0.04% due to recent institutional investments and positive quarterly earnings that beat analysts' expectations. The stock's rise is attributed to several institutional investors purchasing additional shares, reflecting confidence in the company's financial performance after reporting higher-than-expected earnings and revenue growth.
	2024-10-25	-2.72 %
DaVita Inc. (DVA) stock fell by 2.72% as Dumont & Blake Investment Advisors LLC significantly reduced its holdings in the company by over 50% during the third quarter.